FNDC4 (human) ELISA Kit
|Synonyms||Fibronectin Type III Domain-containing Protein 4; Fibronectin Type III Repeat-containing Protein 1; Fc Soluble FNDC4; FcsFNDC4|
|Application Set||Quantitative ELISA|
Detects human FNDC4 in serum, plasma and cell culture supernatant. It cross-reacts with mouse, rat, monkey and dog FNDC4. It does not cross-react with human, mouse or rat FNDC5 / Irisin.
1 x 96 wells
|Range||0.078 to 5ng/ml|
Cell Culture Supernatant
|Other Product Data||
UniProt link Q9H6D8: FDNC4 (human)
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||+4°C|
After standard reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Plate and reagents should reach room temperature before use.
|Use/Stability||12 months after the day of manufacturing. See expiry date on ELISA Kit box.|
|Product Specification Sheet|
Irisin is a recently described exercise-induced hormone secreted by skeletal muscle in mice and humans. Irisin activates beige fat cells (beige cells have a gene expression pattern distinct from either white or brown fat and are preferentially sensitive to the polypeptide hormone irisin). Irisin is cleaved from the type I membrane protein FNDC5 and improves systemic metabolism by increasing energy expenditure. FNDC4 is an ortholog of FNDC5 with 50% identity and 86% similarity compared to Irisin. FNDC4 as well as FNDC5 are extremely well conserved between species. The human FNDC4 gene is highly enriched in liver, brain tissue and adipocytes. FNDC4 is a factor with direct therapeutic potential in inflammatory bowel disease and possibly other inflammatory diseases.
Recently, a new role of FNDC4 as a hepatokine has been published. Liver primarily controls the circulating levels of FNDC4 showing tight correlation with insulin sensitivity. In addition, a new orphan adhesion G protein-coupled receptor 116 (GPR116) has been identified as a receptor of FNDC4 in white adipose tissue (WAT), thereby establishing an endocrine FNDC4-GPR116 axis in the control of systemic glucose homeostasis. Moreover, the FNDC4-GPR116 axis is impaired in diabetic patients and therapeutic injections of recombinant Fc-FNDC4 into pre-diabetic mice corrected pre-diabetic hyperglycemia.
FNDC4 is a factor with direct therapeutic potential in inflammatory bowel disease and possibly other inflammatory diseases and is a potential biomarker for different inflammatory, metabolic diseases as well as some cancers (e.g. Glioblastoma).